Dasatinib Amorphous Solid Dispersion for pH-Independent Oral Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dasatinib formulations, such as SPRYCEL, are affected by co-administration with gastric acid-reducing agents, leading to reduced efficacy and significant pharmacokinetic variability, necessitating restrictive patient treatment protocols.
Innovation Solution
Development of amorphous solid dispersions (ASDs) of dasatinib with polymers that enhance solubility and stability, allowing co-administration with gastric acid-reducing agents without efficacy loss and reducing inter- and intra-patient variability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If crystalline dasatinib monohydrate is used in immediate-release formulation, then the formulation is simple and stable, but oral bioavailability is strongly affected by gastric acid-reducing agents and shows high inter- and intra-patient variability
Solution Approach 1:
The patent transforms dasatinib from its crystalline form to an amorphous form, fundamentally changing the physical state parameter. This amorphous state eliminates the pH-dependent solubility issues that plague crystalline forms, allowing consistent bioavailability regardless of gastric pH conditions. The amorphous solid dispersion maintains drug stability while improving dissolution and absorption characteristics.
Solution Approach 2:
The patent creates a composite material system by dispersing dasatinib within a polymer matrix. This solid dispersion combines the drug with excipients that provide structural support and control release, forming a composite that delivers consistent bioavailability. The polymer-dasatinib composite eliminates the need for restrictive co-administration warnings while maintaining formulation stability.
2Ease of operation
If gastric acid-reducing agents are co-administered with crystalline dasatinib, then patient comfort is improved, but dasatinib concentrations decrease and efficacy is reduced
Solution Approach 1:
The patent converts the harmful interaction between gastric acid reducers and dasatinib into a beneficial outcome. By using amorphous dasatinib in a solid dispersion, the formulation becomes insensitive to gastric pH changes, allowing patients to take gastric acid-reducing agents for comfort without compromising dasatinib efficacy. The harm of pH-dependent solubility is transformed into the benefit of pH-independent delivery.
Solution Approach 2:
Instead of restricting patients from taking gastric acid-reducing agents (the conventional approach), the patent inverts the strategy by creating a formulation that works independently of gastric pH. The amorphous solid dispersion maintains consistent drug release and absorption whether gastric acidity is high or low, eliminating the need for restrictive co-administration warnings.
3Manufacturing precision
If crystalline dasatinib formulation is used, then manufacturing is straightforward, but there is considerable inter- and intra-patient variability in pharmacokinetic parameters
Solution Approach 1:
The patent changes the physical state parameter of dasatinib from crystalline to amorphous, which fundamentally alters dissolution and absorption characteristics. This parameter change reduces pharmacokinetic variability by eliminating crystal lattice energy differences that cause variable dissolution rates. The amorphous state provides more consistent drug release and absorption across different patients and dosing occasions.
Solution Approach 2:
The patent employs a composite solid dispersion system where dasatinib is dispersed in a polymer matrix. This composite structure provides controlled release and consistent dissolution behavior, reducing inter- and intra-patient pharmacokinetic variability. The polymer-dasatinib composite ensures predictable drug release profiles while maintaining manufacturing feasibility through established solid dispersion techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ASDs provide stable and effective dasatinib delivery, maintaining efficacy regardless of gastric pH and reducing variability, enabling flexible treatment regimens.
Implementation Method 1
amorphous solid dispersions (ASDs) of dasatinib with polymers that enhance solubility and stability
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.